Peer Review History
| Original SubmissionApril 12, 2021 |
|---|
|
PONE-D-21-11786 Healthcare professionals’ online searches of children’s oseltamivir in primary and specialized care PLOS ONE Dear Dr. Mukka, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. The manuscript has been evaluated by two reviewers, and their comments are available below. The reviewers have raised a number of concerns that need attention. They request additional information on the utility of this data in assessment of influenza severity, the non-qualitative assessment methods used in this study, sources of information for searches, research objectives/rationale, and various other moderate comments on manuscript structure and discussion. Could you please revise the manuscript to carefully address the concerns raised? Please submit your revised manuscript by Nov 28 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Sebastian Shepherd Associate Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. Thank you for stating the following in the Competing Interests section: "MK has held various trustee positions in the Finnish Medical Society Duodecim since the late 1990s. OH has held various trustee positions in the Finnish Medical Society Duodecim and Duodecim Medical Publications Ltd since 2009 and is a partner at iHealth Finland Ltd. The other authors have no competing interests." Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests). If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared. Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf. 3. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript. 4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: No Reviewer #2: No ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: There is always a need for new sources of influenza and respiratory virus surveillance data. This study provides evidence of generally good alignment between physician searches related to oseltamivir use in children and other influenza surveillance sources based purely on visual review of time series data. My overarching comments are the following. The authors should make clearer exactly how and in what circumstances this data type may be informative for influenza severity– e.g., to assess severity. I also think some of the results that they highlight are not particularly interesting and it would be best to focus on recommendations for using these data. Their prior work (ref 18) used quantitative methods to assess similar data – it is not clear why they have not employed those methods in this study. Other specific comments are below. Abstract I recommend highlighting here that the intent of the study is to assess whether these search data can be used for surveillance purposes. I believe that is the objective of the study and that the text of the objective and rationale sections should be swapped. The absolute numbers of searches vs diagnoses is not the most important results to highlight. I also don’t think primary vs specialized care based searches are key findings to include in the abstract – unless you make clear that specialized includes hospital care (see comment below). Introduction Some editing of the introduction would make the information flow better – either rearrange so influenza and oseltamivir is introduced first, or add paragraph breaks. Right now the first paragraph is muddled. Lines 51-52 – Seems unnecessary to mention a company (Google) three times – would instead just refer to Google Flu Trends once. Lines 55-56 – Could be omitted as this is well understood background information. Since the introduction explains that “specialized care” includes hospital/inpatient based care, and “primary care” seems to only be ambulatory/outpatient, consider calling the specialized care category “specialized and hospital care”. That is an important distinction and makes interpreting the results from the two categories more meaningful. Much of the information in lines 60-83 should be in the Methods section. Methods There are no quantitative methods applied in the study. Visual examination of trends and general comparisons of counts of data is all that is presented, yet they have conducted what appears to be a very similar study previously (ref #18) and applied quite different methods. Results Figures 1 and 2 can be combined. Line 114 – 115 – I’m not sure why a “higher” peak for searches, based on counts, compared to other data sources is important to highlight. Timing of the different data sources is key, as well as what the relative trends are for primary vs specialized and hospital based care – i.e., severity of the season. If the specialized searches for oseltamivir start to appear sooner than other indicators of activity, that is important to highlight. Commenting on what is known about the severity of the seasons you studied would also be useful – to help readers understand how such data can help elucidate influenza activity per season, in “real time”. The peak of specialized searches in the spring of the 2013-14 season does not align with diagnoses or lab reports – what is your hypothesis? This is mentioned in the results but never discussed. This may just be a data anomaly but it is quite evident and needs to be addressed in some way. Reviewer #2: Dear editor, Thank you for providing me with this opportunity to review the mmanuscript titled “Healthcare professionals’ online searches of children’s oseltamivir in primary and specialized care” submitted to Plos One journal. In their interesting work, authors have focused on trying to establish a relationship between the number of searches in the primary and specialized care for oseltamivir and the recorded cases of flu cases in children. This study is valuable because the findings can potentially contribute to the effective prediction of flu pandemics using the frequency of searches for a specific term/phrase. I believe that this manuscript can be considered for further review with additional work, and I do not suggest publication in its current form. I have made detailed comments related to each section of the manuscript below. This manuscript presents a lack of rigorous statistical analysis and an underdeveloped methodology, which need special attention. Title: Suggestions: Change the title to something more generalizable that shows the usefulness of online search results for flu outbreak detection/prediction Keywords Correct “speralized care” to “Specialized care” Abstract Please consider these comments for the abstract and apply those to the body of the manuscript wherever applicable. Well-constructed and organized, overall. Important notes: Lines 24-30: The introductory sentences in the “Objective” section do not align correctly with the research objective. More specifically, the last sentence needs to be changed to reflect the objective of this research (closer to the “Rationale”). Lines 34-38: Include the source of information/ data for both online searches and the recorded number of cases. Lines 39-44: Results need some rigorous statistical analysis. At least, the correlation between the number of searches and the number of recorded cases should be considered. Moreover, if possible additional variables for regression analysis are suggested. Probably a formula can be developed to predict the number of cases using the frequency of searches. Lines 45-46: The conclusion is stated in a form that suggests a binary outcome/incident as yes/no. It should be rephrased as a directional association. More searches= more reported cases (A positive correlation between the frequency of searches and the # of reported cases) Introduction Overall the content of the introduction section is satisfactory. However, the organization and flow are relatively heavy to digest. Please consider using different paragraphs for each of the following content in the following order: 1- Influenza (include # of annual cases in Finland (or Prevalence rate), deaths, plus the burden of disease in terms of cost to the healthcare system. 2- Different options for Online searches, pros cons. 3- Details about the setting (Finish healthcare system) relevant to the topic. 4- The rationale for the need for this research and its expected value added to literature/practice. Material and Methods This section is poorly developed and need much work, including: 1- Suggest adding/ or moving some content from the introduction and adding a “Setting” sub-heading to discuss the study setting. 2- The data sources for online searches and recorded cases should be included here. 3- The rationale and logic behind choosing this medication (oseltamivir) and why this one(and not other medications/ keywords?) should be clarified. 4- Important: The analysis is insufficient. At least, the correlation between the number of searches and the number of recorded cases should be considered. Moreover, if possible additional variables for regression analysis are suggested. Probably a formula can be developed to predict the number of cases using the frequency of searches. Line 102: change “laboratory positive findings” to “positive laboratory findings” Results The results section needs additional work. Important: As a result of substantial changes suggested to the “Methods” section, the “Results” section also needs more development. Begin by including the descriptive statistics about the # of searches. Then, expand with correlation/regression findings. Some charts can be useful here Line 114 and elsewhere: The season 2012/13 needs to be written transparently. For example, the phrase “In specialized care 2012/13 and 2013/14,” is confusing. Please use year and season to make these statements easy to understand. Line 115: Please rewrite this phrase “a wider scale of months before and after these seasons”. It’s a bit unclear. Discussion The discussion section talks about the potential reasons behind why searches are more/less in primary/specialized settings and probably why the reported cases are different in these settings. However, there is no discussion about the uses of these search result for prediction and potential confounders that can impact the accuracy/ issues of using these search results to predict the number of cases. Moreover, other studies/ applications similar to this research should be included and discussed here. Lines 140-141: This statement does not reflect the relative size of the primary and specialized care. The total number of practitioners in different levels (primary/specialized care) should be included to make a legitimate comparison. More can be discussed here by knowing the size of each care level. Needs to be corrected “However, our study found that professionals in primary care use PD as much as their colleagues in specialized care” Conclusions Change based on the results from additional statistical analysis leaned toward the prediction power of the search for oseltamivir in actual flu cases. The suggestion for future research in other diseases is proper. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: Yes: Ahmad Khanijahani [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.
|
| Revision 1 |
|
PONE-D-21-11786R1Online searches of children’s oseltamivir in public primary and specialized care ― Detecting influenza outbreaks in Finland using dedicated databases for health care professionalsPLOS ONE Dear Dr. Mukka, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ============================== We have the response from the reviewers assigned for your revised manuscript. Overall, reviewers indicated that the revisions made by the authors addressed most of the questions raised by the first two reviewers. Moreover, I reviewed your revised manuscript, and I believe that with minor revisions, it can be considered for publication Please consider the points made by the new reviewer (#4) and submit a revised version of your manuscript. Please also double-check your manuscript for the English language and proofread it thoroughly. ============================== Please submit your revised manuscript by Jun 12 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Ahmad Khanijahani Guest Editor PLOS ONE Journal Requirements: Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #3: (No Response) Reviewer #4: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #3: (No Response) Reviewer #4: Partly ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #3: (No Response) Reviewer #4: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #3: (No Response) Reviewer #4: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #3: (No Response) Reviewer #4: No ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #3: (No Response) Reviewer #4: This article provides the use of prescription antiviral dose look-up as a novel method for surveillance of influenza in children, and is an important and potentially helpful use of understanding influenza in our young populations. There could be more caveats provided around the possible confounders in these methodology: what other conclusions could be drawn from these data? are there any biases which arise from these data which have not been shared? and if so , what direction do they draw the results in? For example the difference in 1.7 in lab diagnostics between settings, but the dose checking was the same- what does this mean? what other explanations are there for this? Could anyone be looking up the does of osteltamivir for other reasons (ie teaching/learning?) Could people be prescribing without looking up the does once they know it? The abstract doesn't read properly, and could do with checking for basic English. However, this is a novel and important finding, and useful for surveillance of influenza in children, and is useful to share as helpful methods for public health practice. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #3: No Reviewer #4: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 2 |
|
Online searches of children’s oseltamivir in public primary and specialized care: Detecting influenza outbreaks in Finland using dedicated databases for health care professionals PONE-D-21-11786R2 Dear Dr. Mukka, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Ahmad Khanijahani Guest Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: |
| Formally Accepted |
|
PONE-D-21-11786R2 Online searches of children’s oseltamivir in public primary and specialized care: Detecting influenza outbreaks in Finland using dedicated databases for health care professionals Dear Dr. Mukka: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Ahmad Khanijahani Guest Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .